Skip to content

Gianluca Mancusi

7 papers in the library · 44 citations · publishing 2022-2026

Papers

Sort Most recent Most cited

Dimensional effect profiles in treatment-resistant depression: A naturalistic, prospective head-to-head comparison of arTMS, esketamine nasal spray, and oral brexpiprazole.

Journal of Affective Disorders July 28, 2026 Giacomo d'Andrea, Clara Cavallotto, Ottavia Susini et al.

Treatment-resistant depression (TRD) is a heterogeneous condition in which symptoms such as anhedonia, rumination, and anxiety contribute to persistent disability. Esketamine nasal spray (ESK-NS), accelerated repetitive transcranial magnetic stimulation (arTMS), and adjunctive brexpiprazole represent novel therapeutic options with distinct mechanisms, though their domain-specific effects in...

DOI: 10.1016/j.jad.2026.122333 (opens in new tab) Full text (opens in new tab) Accelerated rtms artms Brexpiprazole augmentation Treatment-resistant depression trd

Novel psychoactive substances (NPS) as a risk factor for psychosis: A systematic review of the literature

Neuroscience & Biobehavioral Reviews October 19, 2025 Alessio Mosca, Gianluca Mancusi, Stefania Chiappini et al. 6 citations

Novel psychoactive substances (NPS) are increasingly used by young individuals for their psychoactive effects and have been frequently associated with the emergence of psychotic symptoms and schizophrenia spectrum disorders. However, it remains unclear whether NPS use directly increases the risk of psychosis onset or whether individuals with a predisposition to psychosis are more likely to...

DOI: 10.1016/j.neubiorev.2025.106431 (opens in new tab) Psychosis Schizophrenia object-oriented programming Risk factor Synthetic cannabinoids +6

Over-the-counter Psychosis: A Systematic Review of the Misuse of Antihistamines, Cough Medicines, and Decongestants and the Risk of Developing Psychosis

Current Neuropharmacology February 20, 2025 Alessio Mosca, Stefania Chiappini, Gianluca Mancusi et al. 3 citations

BACKGROUND: The widespread availability and accessibility of over-the-counter (OTC) medicines play a vital role in modern healthcare systems, enabling individuals to manage minor health concerns independently. However, certain OTC medications possess pharmacological properties that render them susceptible to misuse and abuse, including stimulants, laxatives, sedatives, and opiate-containing...

Piperazine Abuse and Psychosis: A Systematic Review of the Literature

Psychiatry International September 20, 2024 Alessio Mosca, Stefania Chiappini, Andrea Miuli et al. 5 citations

Background: Piperazines, synthetic compounds known for their stimulant and hallucinogenic effects, have gained prominence among novel psychoactive substances (NPS) and are frequently associated with adverse psychiatric outcomes, including psychosis. Methods: A systematic review of the literature available up to 23 May 2024 was conducted, using the PubMed, Scopus, and Web of Science databases,...

DOI: 10.3390/psychiatryint5030040 (opens in new tab) Psychosis Systematic review Piperazine Medline +1

Aberrant salience in cannabis-induced psychosis: a comparative study

Frontiers in Psychiatry January 8, 2024 Valerio Ricci, Ilenia di Muzio, Franca Ceci et al.

Background Natural Cannabis (NC) and Synthetic Cannabinoids (SCs) use can increase the risk and exacerbate the course of psychotic disorders. These could be influenced by the Aberrant Salience (AS) construct. It refers to an excess of attribution of meaning to stimuli that are otherwise regarded as neutral, thereby transform them into adverse, dangerous, or mysterious entities. This leads the...

Rethinking ketamine and esketamine action: Are they antidepressants with mood-stabilizing properties?

European Neuropsychopharmacology May 2023 Giacomo d'Andrea, Mauro Pettorruso, Giorgio Di Lorenzo et al.

Ketamine and esketamine, the S-enantiomer of the racemic mixture, have recently generated considerable interest as potential therapeutic agents for Treatment-Resistant Depression (TRD), a complex disorder that includes various psychopathological dimensions and distinct clinical profiles (e.g., comorbid personality disorder, bipolar spectrum, dysthymic disorder). This perspective article...

DOI: 10.1016/j.euroneuro.2023.02.010 (opens in new tab) Full text (opens in new tab) Esketamine Bipolar depression Mood stabilizers Rapid-acting therapies +1

Ibogaine/Noribogaine in the Treatment of Substance Use Disorders: ASystematic Review of the Current Literature

Current Neuropharmacology October 20, 2022 Alessio Mosca, Stefania Chiappini, Andrea Miuli et al. 30 citations

BACKGROUND: Ibogaine and noribogaine are psychedelic substances with dissociative properties naturally occurring in plants of the Apocynaceae family. Research has shown their efficacy in treating substance use disorders (SUD), particularly in opiate detoxification, but their efficacy and toxicity are still unclear. OBJECTIVE: This review aims to assess the anti-addictive role of ibogaine and...